Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dalpiciclib|DRUG: Pyrotinib|DRUG: Letrozole|DRUG: Fulvestrant
Sponsor: Fudan University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.